FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

On June 22, 2017, the Food and Drug Administration expanded indications for dabrafenib and trametinib to include treatment of patients with metastatic non‐small cell lung cancer (NSCLC) harboring BRAF V600E mutations. Approval was based on results from an international, multicenter, multicohort, non...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Odogwu, Lauretta, Mathieu, Luckson, Blumenthal, Gideon, Larkins, Erin, Goldberg, Kirsten B., Griffin, Norma, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Jiang, Xiaoping, Rodriguez, Lisa, McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2018
Fag:
Regulatory Issues: FDA
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067947/
https://ncbi.nlm.nih.gov/pubmed/29438093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0642
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker